Mogamulizumab
Visão determinística da entidade fonte YAML. A autoridade clínica permanece com os IDs de fonte citados e estado de assinatura do revisor.
| ID | DRUG-MOGAMULIZUMAB |
|---|---|
| Tipo | Fármaco |
| Alegais | PodelegeoМогамулізумаб |
| Estado | reviewed 2026-04-25 | pending_clinical_signoff |
| Doenças | DIS-ATLL DIS-MF-SEZARY |
| Fontes | SRC-NCCN-BCELL-2025 |
Fatos sobre as drogas
| Classe | Defucosylated humanized anti-CCR4 monoclonal antibody (enhanced ADCC) |
|---|---|
| Mecanismo | Defucosylated IgG1 against CCR4 — receptor expressed on Th2 / Treg cells and on malignant T-cells in MF/Sézary, ATLL. Defucosylation enhances ADCC ~100-fold via FcγRIIIa engagement → potent depletion of CCR4+ cells. Highest activity in Sézary syndrome (blood compartment) where CCR4 expression is most uniform. |
| Dose típica | MF/Sézary: 1.0 mg/kg IV over ≥1 hour weekly × 5 (induction), then every 2 weeks until progression or unacceptable toxicity. |
| Ucrânia registada | Falso |
| NSZU reembolsado | Falso |
| Ucrânia verificada pela última vez | 2026-04-27 |
Avisos
- Reações cutâneas graves (incluindo SJS/TEN)
- Aumento do risco de GVHD Grau 3-4 se alo-SCT planejado a jusante — discutir com a equipe de transplante
Notas
MAVORIC trial (Kim 2018): mogamulizumab vs vorinostat in r/r MF/Sézary — superior PFS especially in Sézary syndrome (blood compartment response). 1L use in advanced MF/Sézary emerging (NCCN). Ukraine: NOT registered → import-only with МОЗ exception or clinical-trial enrollment. Mandatory dermatology partnership for skin AE management.
Usado por
Indicação
IND-ATLL-1L-AGGRESSIVE- IND-ATLL-1L-AGGRESSIVE
Esquema terapêutico
REG-MOGAMULIZUMAB- Mogamulizumab em monoterapia (1.0 mg/kg IV semanal × 5, então q2 semanas)